Sage Journals: Discover world-class research

Abstract

This is a systematic review examining the management of opioid-induced central side effects. It has been conducted as part of a larger European Palliative Care Research collaborative review into the use and role of opioids in cancer pain. The review process identified 26 studies that met the inclusion criteria. The overall quality of the data was low and the few recommendations that can be made are weak and require confirmatory studies.

The main central side effects examined were sedation, cognitive failure, sleep disturbance and myoclonus. Overall there is limited evidence for the use of methylphenidate in counteracting opioid-induced sedation and cognitive disturbance. No clear recommendations can be made concerning other individual drugs for the management of any of the central side effects examined.

Given the lack of available data from this review there need to be further prospective controlled trials to confirm or refute these findings.

Keywords

analgesics central nervous system stimulants opioid

Get full access to this article

View all access options for this article.

References

Moher

Liberati

Tetzlaff

Altman

. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009; 339: b2535–b2535.

Bruera

Brenneis

Paterson

MacDonald

. Narcotics plus methylphenidate (Ritalin) for advanced cancer pain. Am J Nurs 1988; 88: 1555–1556.

Bruera

Brenneis

Paterson

MacDonald

. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manag 1989; 4: 3–6.

De Conno

Caraceni

Martini

Spoldi

Salvetti

Ventafridda

. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47: 337–339.

Bruera

Chadwick

Brenneis

Hanson

MacDonald

. Methylphenidate associated with narcotics for the treatment of cancer pain. Canc Treat Rep 1987; 71: 67–70.

Bruera

Fainsinger

MacEachern

Hanson

. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50: 75–77.

Bruera

Miller

Macmillan

Kuehn

. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992b; 48: 163–166.

Yee

Berde

. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manag 1994; 9: 122–125.

Wilwerding

Loprinzi

Mailliard

. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Canc 1995; 3: 135–138.

10.

Kreeger

Duncan

Cowap

. Psychostimulants used for opioid-induced drowsiness. J Pain Symptom Manag 1996; 11(1): 1–2.

11.

Mercadante

Serretta

Casuccio

. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manag 2001; 21: 369–372.

12.

Slatkin

Rhiner

Bolton

. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manag 2001; 21: 425–438.

13.

Bruera

Strasser

Shen

. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manag 2003; 26: 1049–1054.

14.

Slatkin

Rhiner

. Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. J Support Oncol 2003; 1: 53–63.

15.

Slatkin

Rhiner

. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manag 2004; 27: 268–273.

16.

Sylvester

Levitt

Steen

. Opioid-induced muscle activity: implications for managing chronic pain [see comment]. Ann Pharmacother 1995; 29: 1118–1121.

17.

Cartwright

Hesse

Jackson

. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manag 1993; 8: 492–495.

18.

Glavina

Robertshaw

. Myoclonic spasms following intrathecal morphine. Anaesthesia 1988; 43: 389–390.

19.

Hagen

Swanson

. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies [see comment]. J Pain Symptom Manag 1997; 14: 51–58.

20.

Krames

Gershow

Glassberg

. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer 1985; 56: 696–702.

21.

Mercadante

. Dantrolene treatment of opioid-induced myoclonus. Anesth Analg 1995; 81: 1307–1308.

22.

Mercadante

Villari

Fulfaro

. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Canc 2001; 9: 205–206.

23.

Parkinson

Bailey

Little

Mueller

. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990; 72: 743–745.

24.

Rozan

Kahn

Warfield

. Epidural and intravenous opioid-induced neuroexcitation. Anesthesiology 1995; 83: 860–863.

25.

Sjogren

Jonsson

Jensen

Drenck

Jensen

. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93–97.

26.

Passik

Cooper

. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manag 1999; 17: 219–223.

27.

Shinno

Matsuoka

Yamamoto

. Successful treatment with quetiapine for delirium in terminally ill cancer patients. Psychogeriatrics 2007; 7: 64–68.

28.

Stillman

Moulin

Foley

. Paradoxical pain following high-dose spinal morphine. Pain 1987; 30(Suppl 1): S389–S389.

29.

Sjogren

Jonsson

Jensen

Drenck

Staehelin Jensen

. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93–97.

30.

Dudgeon

Bruera

Gagnon

. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manag 2007; 33: 365–371.

31.

Mitra

. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag 2008; 4: 123–130.

32.

Silverman

. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009; 12: 679–684.

33.

Ali

. Hyperalgesic response in a patient receiving high concentrations of spinal morphine. Anesthesiology 1986; 65: 449–449.

34.

Bruera

Franco

Maltoni

Watanabe

Suarez-Almazor

. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manag 1995; 10: 287–291.

35.

Davis

Shaiova

Angst

. When opioids cause pain [see comment]. J Clin Oncol 2007; 25: 4497–4498.

36.

Ito

Liao

. Myoclonus associated with high-dose parenteral methadone. J Palliat Med 2008; 11: 838–841.

37.

Lawlor

Gagnon

Mancini

. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study [see comment]. Arch Intern Med 2000; 160: 786–794.

38.

MacDonald

Der

Allan

Champion

. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993; 53: 353–355.

39.

Mercadante

Arcuri

. Hyperalgesia and opioid switching. Am J Hospice Palliat Med 2005; 22: 291–294.

40.

Mercadante

Ferrera

Villari

Arcuri

. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manag 2003; 26: 769–775.

41.

Mercadante

Villari

Ferrera

. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manag 2003; 25: 302–305.

42.

Morita

Tei

Inoue

. Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med 2003; 6: 557–563.

43.

Sjogren

Jensen

. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59: 313–316.

44.

Wilson

Reisfield

. Morphine hyperalgesia: a case report. Am J Hospice Palliat Med 2003; 20: 459–461.

45.

Vorobeychik

Chen

Bush

Mao

. Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008; 9: 724–727.

46.

Breitbart

Marotta

Platt

. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of Delerium in hospitalized AIDS patients. Am J Psychiatry 1996; 153: 231–237.

47.

Seneff

Mathews

. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother 1995; 29: 690–693.

48.

Battaglia

Moss

Rush

. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15: 335–340.

49.

Olofsson

Weitzner

Valentine

Baile

Meyers

. A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Canc 1996; 4: 351–357.

50.

Akechi

Uchitomi

Okamura

. Usage of haloperidol for delirium in cancer patients. Support Care Cancer 1996; 4: 390–392.

51.

Vella-Brincat

Macleod

. Haloperidol in palliative care. Palliat Med 2004; 18: 195–201.

52.

Ripamonti

Bruera

. CNS adverse effects of opioids in cancer patients: guidelines for treatment. CNS Drugs 1997; 8: 21–37.

53.

Vella-Brincat

MacLeod

. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother 2007; 21: 15–25.

54.

Cherny

Ripamonti

Pereira

. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542–2554.

55.

Lawlor

. The panorama of opioid-related cognitive dysfunction in patients with cancer. Cancer 2002; 94: 1836–1853.

European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation,cognitive impairment and myoclonus?

Abstract

Keywords

Get full access to this article

References